Tumor-suppressive and promoting function of transforming growth factor beta

Frontiers in Bioscience

Volumn 9, Issue , 2004, Pages 1925-1935

  Sun, LuZhe ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antagonists; Cancer; Review; TGF beta; Tumor progression

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; COLON CARCINOMA; DRUG EFFICACY; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; METASTASIS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL; TUMOR PROMOTION; XENOGRAFT; ANIMAL; CARCINOMA; DISEASE COURSE; DRUG ANTAGONISM; MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARCINOMA; DISEASE PROGRESSION; HUMANS; MICE; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS;

EID: 2442696844     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1382     Document Type: Review

References (121)

1. Piek, E., C. H. Heldin and P. ten Dijke: Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 13, 2105-2124 (1999)
2. Chen, C., X. F. Wang and L. Z. Sun: Expression of transforming growth factor beta type III receptor restores autocrine TGF beta1 activity in human breast cancer MCF-7 cells. J Biol Chem 272, 12862-12867 (1997)
3. Lopez-Casillas, F., J. L. Wrana and J. Massague: Betaglycan presents ligand to the TGF beta signaling receptor. Cell 73, 1435-1444 (1993)
4. Wang, X. F., H. Y. Lin, E. Ng-Eaton, J. Downward, H. F. Lodish and R. A. Weinberg: Expression cloning and characterization of the TGF-beta type III receptor. Cell 67, 797-805 (1991)
5. Fukushima, D., R. Butzow, A. Hildebrand and E. Ruoslahti: Localization of transforming growth factor beta binding site in betaglycan. Comparison with small extracellular matrix proteoglycans. J Biol Chem 268, 22710-22715 (1993)
6. Lopez-Casillas, F., H. M. Payne, J. L. Andres and J. Massague: Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 124, 557-568 (1994)
7. Wrana, J. L., L. Attisano, R. Wieser, F. Ventura and J. Massague: Mechanism of activation of the TGF-beta receptor. Nature 370, 341-347 (1994)
8. Massagué, J: TGF-β signal transduction. Annu Rev Biochem 67, 753-791 (1998)
9. Massague, J. and Y. G. Chen: Controlling TGF-beta signaling. Genes and Development 14, 627-644 (2000)
10. Moses, H. L., E. Y. Yang and J. A. Pietenpol: TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63, 245-247 (1990)
11. Roberts, A. B. and M. B. Sporn: The transforming growth factor-betas. In: Peptide growth factors and their receptors I. Eds: Sporn MB, Roberts AB, Springer-Verlag, Heidelberg 419-472 (1991)
12. Roberts, A. B., M. A. Anzano, L. C. Lamb, J. M. Smith and M. B. Sporn: New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci USA 78, 5339-5343 (1981)
13. Moses, H. L., R. F. Tucker, E. B. Leof, R. J. Coffey, Jr., J. Halper and G. D. Shipley: Type-beta transforming growth factor is a growth stimulator and a growth inhibitor. In: Cancer Cells. Eds: Feramisco J, Ozanne B, Stiles C, Cold Spring Harbor Laboratory Press, Cold Spring Harbor 65-71 (1985)
14. Arteaga, C. L., R. J. Coffey, Jr., T. C. Dugger, C. M. McCutchen, H. L. Moses and R. M. Lyons: Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta. Cell Growth Differ 1, 367-374 (1990)
15. Glick, A. B., K. C. Flanders, D. Danielpour, S. H. Yuspa and M. B. Sporn: Retinoic acid induces transforming growth factor-beta 2 in cultured keratinocytes and mouse epidermis. Cell Regul 1, 87-97 (1989)
16. Hafez, M. M., D. Infante, S. Winawer and E. Friedman: Transforming growth factor beta 1 acts as an autocrine-negative growth regulator in colon enterocytic differentiation but not in goblet cell maturation. Cell Growth Differ 1, 617-626 (1990)
17. Wu, S. P., D. Theodorescu, R. S. Kerbel, J. K. Willson, K. M. Mulder, L. E. Humphrey and M. G. Brattain: TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 116, 187-196 (1992)
18. Wu, S. P., L. Z. Sun, J. K. Willson, L. Humphrey, R. Kerbel and M. G. Brattain: Repression of autocrine transforming growth factor beta 1 and beta 2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Differ 4, 115-123 (1993)
19. Markowitz, S., J. Wang, L. Myeroff, R. Parsons, L. Sun, J. Lutterbaugh, R. S. Fan, E. Zborowska, K. W. Kinzler, B. Vogelstein, M. G. Brattain and J. K. V. Willson: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338 (1995)
20. Myeroff, L. L., R. Parsons, S. J. Kim, L. Hedrick, K. R. Cho, K. Orth, M. Mathis, K. W. Kinzler, J. Lutterbaugh, K. Park, Y. J. Bang, H. Y. Lee, J. G. Park, H. T. Lynch, A. B. Roberts, B. Vogelstein and S. D. Markowitz: A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55, 5545-5547 (1995)
21. Abe, T., H. Ouyang, T. Migita, Y. Kato, M. Kimura, K. Shiiba, M. Sunamura, S. Matsuno and A. Horii: The somatic mutation frequency of the transforming growth factor beta receptor type II gene varies widely among different cancers with microsatellite instability. Eur J Surg Oncol 22, 474-477 (1996)
22. Tomita, S., S. Deguchi, T. Miyaguni, Y. Muto, T. Tamamoto and T. Toda: Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features. Breast Cancer Res Treat 53, 33-39 (1999)
23. Eisma, R. J., J. D. Spiro, S. E. von Biberstein, R. Lindquist and D. L. Kreutzer: Decreased expression of transforming growth factor beta receptors on head and neck squamous cell carcinoma tumor cells. Am J Surg 172, 641-645 (1996)
24. Franchi, A., O. Gallo, I. Sardi and M. Santucci: Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis. J Clin Pathol 54, 201-204 (2001)
25. Gobbi, H., W. D. Dupont, J. F. Simpson, W. D. Plummer, P. A. Schuyler, S. J. Olson, C. L. Arteaga and D. L. Page: Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 91, 2096-2101 (1999)
26. Chang, J., K. Park, Y. J. Bang, W. S. Kim, D. Kim and S. J. Kim: Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res 57, 2856-2859 (1997)
27. Sun, L., G. Wu, J. K. Willson, E. Zborowska, J. Yang, I. Rajkarunanayake, J. Wang, L. E. Gentry, X. F. Wang and M. G. Brattain: Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269, 26449-26455 (1994)
28. Wang, J., L. Sun, L. Myeroff, X. Wang, L. E. Gentry, J. Yang, J. Liang, E. Zborowska, S. Markowitz, J. K. Willson and M. G. Brattain: Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 270, 22044-22049 (1995)
29. Chen, T., J. Triplett, B. Dehner, B. Hurst, B. Colligan, J. Pemberton, J. R. Graff and J. H. Carter: Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 61, 4679-4682 (2001)
30. Wang, D., T. Kanuma, H. Mizunuma, F. Takama, Y. Ibuki, N. Wake, A. Mogi, Y. Shitara and S. Takenoshita: Analysis of specific gene mutations in the transforming growth factor- beta signal transduction pathway in human ovarian cancer. Cancer Res 60, 4507-4512 (2000)
31. Kang, S. H., Y. J. Bang, Y. H. Im, H. K. Yang, D. A. Lee, H. Y. Lee, H. S. Lee, N. K. Kim and S. J. Kim: Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer. Oncogene 18, 7280-7286 (1999)
32. Wang, J., W. Han, E. Zborowska, J. Liang, X. Wang, J. K. V. Willson, L. Sun and M. G. Brattain: Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem 271, 17366-17371 (1996)
33. Hahn, S. A., M. Schutte, A. T. Hoque, C. A. Moskaluk, L. T. da Costa, E. Rozenblum, C. L. Weinstein, A. Fischer, C. J. Yeo, R. H. Hruban and S. E. Kern: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353 (1996)
34. Hahn, S. A., A. T. Hoque, C. A. Moskaluk, L. T. da Costa, M. Schutte, E. Rozenblum, A. B. Seymour, C. L. Weinstein, C. J. Yeo, R. H. Hruban and S. E. Kern: Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 56, 490-494 (1996)
35. Maitra, A., K. Molberg, J. Albores-Saavedra and G. Lindberg: Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol 157, 1105-1111 (2000)
36. Miyaki, M., T. Iijima, M. Konishi, K. Sakai, A. Ishii, M. Yasuno, T. Hishima, M. Koike, N. Shitara, T. Iwama, J. Utsunomiya, T. Kuroki and T. Mori: Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18, 3098-3103 (1999)
37. Takagi, Y., H. Kohmura, M. Futamura, H. Kida, H. Tanemura, K. Shimokawa and S. Saji: Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 111, 1369-1372 (1996)
38. Eppert, K., S. W. Scherer, H. Ozcelik, R. Pirone, P. Hoodless, H. Kim, L. C. Tsui, B. Bapat, S. Gallinger, I. L. Andrulis, G. H. Thomsen, J. L. Wrana and L. Attisano: MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86, 543-552 (1996)
39. Uchida, K., M. Nagatake, H. Osada, Y. Yatabe, M. Kondo, T. Mitsudomi, A. Masuda and T. Takahashi: Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res 56, 5583-5585 (1996)
40. Pierce, D. F., Jr., A. E. Gorska, A. Chytil, K. S. Meise, D. L. Page, R. J. Coffey, Jr. and H. L. Moses: Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A 92, 4254-4258 (1995)
41. Tang, B., E. P. Bottinger, S. B. Jakowlew, K. M. Bagnall, J. Mariano, M. R. Anver, J. J. Letterio and L. M. Wakefield: Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 4, 802-807 (1998)
42. Amendt, C., P. Schirmacher, H. Weber and M. Blessing: Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 17, 25-34 (1998)
43. Bottinger, E. P., J. L. Jakubczak, I. S. Roberts, M. Mumy, P. Hemmati, K. Bagnall, G. Merlino and L. M. Wakefield: Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas. EMBO J 16, 2621-2633 (1997)
44. Go, C., W. He, L. Zhong, P. Li, J. Huang, B. R. Brinkley and X. J. Wang: Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGF beta RII. Oncogene 19, 3623-3631 (2000)
45. Takaku, K., H. Miyoshi, A. Matsunaga, M. Oshima, N. Sasaki and M. M. Taketo: Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res 59, 6113-6117 (1999)
46. Xu, X., S. G. Brodie, X. Yang, Y. H. Im, W. T. Parks, L. Chen, Y. X. Zhou, M. Weinstein, S. J. Kim and C. X. Deng: Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 19, 1868-1874 (2000)
47. Takaku, K., M. Oshima, H. Miyoshi, M. Matsui, M. F. Seldin and M. M. Taketo: Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92, 645-656 (1998)
48. Dang, C. V: c-myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19, 1-11 (1999)
49. Coffey, R. J., Jr., C. C. Bascom, N. J. Sipes, R. Graves-Deal, B. E. Weissman and H. L. Moses: Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Mol Cell Biol 8, 3088-3093 (1988)
50. Mulder, K. M., A. E. Levine, X. Hernandez, M. K. McKnight, D. E. Brattain and M. G. Brattain: Modulation of c-myc by transforming growth factor-beta in human colon carcinoma cells. Biochem Biophys Res Commun 150, 711-716 (1988)
51. Pietenpol, J. A., R. W. Stein, E. Moran, P. Yaciuk, R. Schlegel, R. M. Lyons, M. R. Pittelkow, K. Munger, P. M. Howley and H. L. Moses: TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 61, 777-785 (1990)
52. Chen, C. R., Y. B. Kang, P. M. Siegel and J. Massague: E2F4/5 and p107 as Smad cofactors linking the TGF beta receptor to c-myc repression. Cell 110, 19-32 (2002)
53. Datto, M. B., Y. Li, J. F. Panus, D. J. Howe, Y. Xiong and X. F. Wang: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A 92, 5545-5549 (1995)
54. Hannon, G. J. and D. Beach: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371, 257-261 (1994)
55. Datto, M. B., Y. Yu and X. F. Wang: Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 270, 28623-28628 (1995)
56. Feng, X. H., X. Lin and R. Derynck: Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J 19, 5178-5193 (2000)
57. Pardali, K., A. Kurisaki, A. Moren, P. ten Dijke, D. Kardassis and A. Moustakas: Role of smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 275, 29244-29256 (2000)
58. Reynisdottir, I., K. Polyak, A. Iavarone and J. Massague: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 9, 1831-1845 (1995)
59. Sandhu, C., J. Garbe, N. Bhattacharya, J. Daksis, C. H. Pan, P. Yaswen, J. Koh, J. M. Slingerland and M. R. Stampfer: Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 17, 2458-2467 (1997)
60. Chipuk, J. E., M. Bhat, A. Y. Hsing, J. J. Ma and D. Danielpour: Bcl-xL, blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem 276, 26614-26621 (2001)
61. Rotello, R. J., R. C. Lieberman, A. F. Purchio and L. E. Gerschenson: Coordinated regulation of apoptosis and cell proliferation by transforming growth factor beta 1 in cultured uterine epithelial cells. Proc Natl Acad Sci U S A 88, 3412-3415 (1991)
62. Edlund, S., S. H. Bu, N. Schuster, P. Aspenstrom, R. Heuchel, N. E. Heldin, P. ten Dijke, C. H. Heldin and M. Landstrom: Transforming growth factor-beta 1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell 14, 529-544 (2003)
63. Schuster, N. and K. Krieglstein: Mechanisms of TGF-beta-mediated apoptosis. Cell and Tissue Research 307, 1-14 (2002)
64. Lin, S. Y. and S. J. Elledge: Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113, 881-889 (2003)
65. Yang, H., S. Kyo, M. Takatura and L. Sun: Autocrine transforming growth factor beta suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells. Cell Growth Differ 12, 119-127 (2001)
66. Katakura, Y., E. Nakata, T. Miura and S. Shirahata: Transforming growth factor β triggers two independent-senescence programs in cancer cells. Biochem Biophys Res Commun 255, 110-115 (1999)
67. Wilentz, R. E., C. A. Iacobuzio-Donahue, P. Argani, D. M. McCarthy, J. L. Parsons, C. J. Yeo, S. E. Kern and R. H. Hruban: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60, 2002-2006 (2000)
68. Grady, W. M., A. Rajput, L. Myeroff, D. F. Liu, K. H. Kwon, J. Willis and S. Markowitz: Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 58, 3101-3104 (1998)
69. Tu, W. H., T. Z. Thomas, N. Masumori, N. A. Bhowmick, A. E. Gorska, Y. Shyr, S. Kasper, T. Case, R. L. Roberts, S. B. Shappell, H. L. Moses and R. J. Matusik: The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia 5, 261-277 (2003)
70. Fink, S. P., S. E. Swinler, J. D. Lutterbaugh, J. Massague, S. Thiagalingam, K. W. Kinzler, B. Vogelstein, J. K. V. Willson and S. Markowitz: Transforming growth factor-beta-induced growth inhibition in a smad4 mutant colon adenoma cell line. Cancer Res 61, 256-260 (2001)
71. Yu, L., M. C. Hebert and Y. E. Zhang: TGF-beta receptor-activated p38 MAP kinase mediates smad-independent TGF-beta responses. EMBO J 21, 3749-3759 (2002)
72. Schutte, M., R. H. Hruban, L. Hedrick, K. R. Cho, G. M. Nadasdy, C. L. Weinstein, G. S. Bova, W. B. Isaacs, P. Cairns, H. Nawroz, D. Sidransky, R. A. Casero, Jr., P. S. Meltzer, S. A. Hahn and S. E. Kern: DPC4 gene in various tumor types. Cancer Res 56, 2527-2530 (1996)
73. Murphy, C. S., J. A. Pietenpol, K. Munger, P. M. Howley and H. L. Moses: c-myc and pRB: role in TGF-beta 1 inhibition of keratinocyte proliferation. Cold Spring Harb Symp Quant Biol 56, 129-135 (1991)
74. Zentella, A., F. M. Weis, D. A. Ralph, M. Laiho and J. Massague: Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function. Mol Cell Biol 11, 4952-4958 (1991)
75. Chen, C. R., Y. B. Kang and J. Massague: Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA 98, 992-999 (2001)
76. Reiss, M: TGF-beta and cancer. Microbes and Infection 1, 1327-1347 (1999)
77. Barrett-Lee, P., M. Travers, Y. Luqmani and R. C. Coombes: Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br J Cancer 61, 612-617 (1990)
78. Coombes, R. C., P. Barrett-Lee and Y. Luqmani: Growth factor expression in breast tissue. J Steroid Biochem Mol Biol 37, 833-836 (1990)
79. Daly, R. J., R. J. King and P. D. Darbre: Interaction of growth factors during progression towards steroid independence in T-47-D human breast cancer cells. J Cell Biochem 43, 199-211 (1990)
80. Gorsch, S. M., V. A. Memoli, T. A. Stukel, L. I. Gold and B. A. Arrick: Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52, 6949-6952 (1992)
81. Walker, R. A. and B. Gallacher: Determination of transforming growth factor beta 1 mRNA expression in breast carcinomas by in situ hybridization. J Pathol 177, 123-127 (1995)
82. Friedman, E., L. I. Gold, D. Klimstra, Z. S. Zeng, S. Winawer and A. Cohen: High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 4, 549-554 (1995)
83. Tsushima, H., S. Kawata, S. Tamura, N. Ito, Y. Shirai, S. Kiso, Y. Imai, H. Shimomukai, Y. Nomura, Y. Matsuda and Y. Matsuzawa: High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 110, 375-382 (1996)
84. Steiner, M. S., Z. Z. Zhou, D. C. Tonb and E. R. Barrack: Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 135, 2240-2247 (1994)
85. Wikström, P., P. Stattin, I. Franck-Lissbrant, J. E. Damber and A. Bergh: Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37, 19-29 (1998)
86. Miyamoto, H., Y. Kubota, T. Shuin, S. Torigoe, Y. Dobashi and M. Hosaka: Expression of transforming growth factor-beta 1 in human bladder cancer. Cancer 75, 2565-2570 (1995)
87. Arteaga, C. L., T. Carty-Dugger, H. L. Moses, S. D. Hurd and J. A. Pietenpol: Transforming growth factor beta 1 can induce estrogen- independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 4, 193-201 (1993)
88. Steiner, M. S. and E. R. Barrack: Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 6, 15-25 (1992)
89. Ye, S. C., J. M. Foster, W. H. Li, J. R. Liang, E. Zborowska, S. Venkateswarlu, J. G. Gong, M. G. Brattain and J. V. Willson: Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells. Cancer Res 59, 4725-4731 (1999)
90. Tobin, S. W., K. Douville, U. Benbow, C. E. Brinckerhoff, V. A. Memoli and B. A. Arrick: Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects. Oncogene 21, 108-118 (2002)
91. Cui, W., D. J. Fowlis, S. Bryson, E. Duffie, H. Ireland, A. Balmain and R. J. Akhurst: TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86, 531-542 (1996)
92. Sosroseno, W. and E. Herminajeng: The immunoregulatory roles of transforming growth factor beta. Br J Biomed Sci 52, 142-148 (1995)
93. Torre-Amione, G., R. D. Beauchamp, H. Koeppen, B. H. Park, H. Schreiber, H. L. Moses and D. A. Rowley: A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87, 1486-1490 (1990)
94. Fajardo, L. F., S. D. Prionas, H. H. Kwan, J. Kowalski and A. C. Allison: Transforming growth factor beta1 induces angiogenesis in vivo with a threshold pattern. Lab Invest 74, 600-608 (1996)
95. Yang, E. Y. and H. L. Moses: Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111, 731-741 (1990)
96. Wang, X. J., K. M. Liefer, S. Tsai, B. W. O'Malley and D. R. Roop: Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis. Proc Natl Acad Sci USA 96, 8483-8488 (1999)
97. Stearns, M. E., F. U. Garcia, K. Fudge, J. Rhim and M. Wang: Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 5, 711-720 (1999)
98. Ueki, N., M. Nakazato, T. Ohkawa, T. Ikeda, Y. Amuro, T. Hada and K. Higashino: Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta 1137, 189-196 (1992)
99. Welch, D. R., A. Fabra and M. Nakajima: Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci U S A 87, 7678-7682 (1990)
100. Oft, M., K. H. Heider and H. Beug: TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8, 1243-1252 (1998)
101. Yin, J. J., K. Selander, J. M. Chirgwin, M. Dallas, B. G. Grubbs, R. Wieser, J. Massague, G. R. Mundy and T. A. Guise: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103, 197-206 (1999)
102. Tang, B. W., M. Vu, T. Booker, S. J. Santner, F. R. Miller, M. R. Anver and L. M. Wakefield: TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. Journal of Clinical Investigation 112, 1116-1124 (2003)
103. Tian, F., B. S. DaCosta, W. T. Parks, S. Yoo, A. Felici, B. Tang, E. Pick, L. M. Wakefield and A. B. Roberts: Reduction in smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 63, 8284-8292 (2003)
104. Derynck, R., R. J. Akhurst and A. Balmain: TGF-beta signaling in tumor suppression and cancer progression. Nature Genet 29, 117-129 (2001)
105. Norgaard, P., S. Hougaard, H. S. Poulsen and M. Spang-Thomsen: Transforming growth factor beta and cancer. Cancer Treat Rev 21, 367-403 (1995)
106. Lei, X. F., A. Bandyopadhyay, T. Le and L. Z. Sun: Autocrine TGF beta supports growth and survival of human breast cancer MDA-MB-231 cells. Oncogene 21, 7514-7523 (2002)
107. Shin, I., A. V. Bakin, U. Rodeck, A. Brunet and C. L. Arteaga: Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell 12, 3328-3339 (2001)
108. Arteaga, C. L., S. D. Hurd, A. R. Winnier, M. D. Johnson, B. M. Fendly and J. T. Forbes: Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 92, 2569-2576 (1993)
109. Park, J. A., E. Wang, R. A. Kurt, S. F. Schluter, E. M. Hersh and E. T. Akporiaye: Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther 4, 42-50 (1997)
110. Arteaga, C. L., K. M. Koli, T. C. Dugger and R. Clarke: Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst 91, 46-53 (1999)
111. Bandyopadhyay, A., Y. Zhu, M. L. Cibull, L. W. Bao, C. G. Chen and L. Z. Sun: A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res 59, 5041-5046 (1999)
112. Bandyopadhyay, A., Y. Zhu, S. N. Malik, J. Kreisberg, M. G. Brattain, E. A. Sprague, J. Luo, F. Lopez-Casillas and L. Z. Sun: Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 21, 3541-3551 (2002)
113. Rowland-Goldsmith, M. A., H. Maruyama, T. Kusama, S. Ralli and M. Korc: Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clinical Cancer Research 7, 2931-2940 (2001)
114. Rowland-Goldsmith, M. A., H. Maruyama, K. Matsuda, T. Idezawa, M. Ralli, S. Ralli and M. Korc: Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Molecular Cancer Therapeutics 1, 161-167 (2002)
115. Stander, M., U. Naumann, L. Dumitrescu, M. Heneka, P. Loschmann, E. Gulbins, J. Dichgans and M. Weller: Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther 5, 1187-1194 (1998)
116. Zhao, W. L., M. Kobayashi, W. Ding, L. Yuan, P. Seth, S. Cornain, J. X. Wang, F. Okada and M. Hosokawa: Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II. Cancer Immunology Immunotherapy 51, 381-388 (2002)
117. Yang, Y. A., O. Dukhanina, B. Tang, M. Mamura, J. J. Letterio, J. MacGregor, S. C. Patel, S. Khozin, Z. Y. Liu, J. Green, M. R. Anver, G. Merlino and L. M. Wakefield: Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109, 1607-1615 (2002)
118. Muraoka, R. S., N. Dumont, C. A. Ritter, T. C. Dugger, D. M. Brantley, J. Chen, E. Easterly, L. R. Roebuck, S. Ryan, P. J. Gotwals, V. Koteliansky and C. L. Arteaga: Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109, 1551-1559 (2002)
119. Bandyopadhyay, A., F. Lopez-Casillas, S. N. Malik, J. L. Montiel, V. Mendoza, J. Yang and L. Z. Sun: Antitumor Activity of a Recombinant Soluble Betaglycan in Human Breast Cancer Xenograft. Cancer Res 62, 4690-4695 (2002)
120. Dumont, N. and C. L. Arteaga: Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3, 531-536 (2003)
121. Mundy, G. R: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature Reviews Cancer 2, 584-593 (2002)